Sentences with phrase «in cells from patients»

246/3: 00 Quantitative cell image - based high content screening identifies brain permeable small molecules that rescue peroxisome assembly defects in cells from patients with Zellweger spectrum disorder.

They then examined the effect of a chemical that inhibits SRF and found that glucose uptake rates increased in both mice and human cells — and that the effects were greater in cells from patients who were insulin resistant or had type 2 diabetes.

An analysis of all gene transcription in the cultured cell lines turned up a large gene complex in which gene expression differed conspicuously in cells from patients compared to controls.

«We see this mild increase in Aβ42 in cells from patients with Alzheimer's disease, which seems to be enough to trigger disease processes,» said Young - Pearse, a Harvard Stem Cell Institute - affiliated faculty member at Brigham and Women's Hospital.

When they sequenced the iPS cell lines, they found higher numbers of mitochondrial DNA mutations, particularly in cells from patients older than 60.

In contrast, PD - L1 blockade increased the capacity of Treg cells to multiply (and hence their overall numbers), but only in cells from patients with viremia, i.e. those that had detectable virus in their blood.

In the study, researchers found two drugs, called UNC0638 and UNC0642, capable of activating maternal PWS genes in cells from a patient.

Not exact matches

Researchers from the Sichuan University in Chengdu inserted the re-engineered cells into a lung cancer patient participating in a clinical trial at the West China Hospital on October 28th, according to Nature.

Speaking of Novartis — the company's experimental CTL019, which is expected to be the first approved drug in a revolutionary new cancer treatment space that turns the body's own immune cells into cancer - killers, is already facing some apprehension from doctors and patient groups who are worried about its eventual pricing.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

This new kind of approach to fighting blood cancers is truly personalized; immune T - cells are extracted from patients, genetically tinkered to home in on an destroy cancerous cells, multiplied in a lab, and then jolted back into the patient's body within about two weeks.

«We look forward to leveraging all of our learnings and new capabilities from the initial launch of Kymriah in pediatric and young adult B - cell ALL for this larger group of patients.»

In November the Lancet published the results of an international research project whereby a Colombian lady received a new trachea (windpipe) which had been grown from a donor trachea (as it were, a «scaffold») repopulated with stem cells, for the very first time, from the patient's own body.

As we read this history, the furor over stem cells was fueled by numerous factors: the near - universal human desire for magic; patients» desperation in the face of illness and their hope for cures; the belief that biology can now do anything; the reluctance of scientists to accept any limits (particularly moral limits) on their research; the impact of big money from biotech stocks, patents, and federal funding; the willingness of America's elite class to use every means possible to discredit religion in general; and the need to protect the unlimited abortion license by accepting no protections of unborn human life.

If we can make pluripotent ES - like cells directly from patients» somatic cells, that will be a tremendous advantage in regenerative medicine.»

In 1999, Anthony Atala grew a colony of bladder cells, taken from a biopsy and seeded on a «scaffold» in the shape of a patient's own bladdeIn 1999, Anthony Atala grew a colony of bladder cells, taken from a biopsy and seeded on a «scaffold» in the shape of a patient's own bladdein the shape of a patient's own bladder.

Not only were there no adverse effects from the transplanted cells — this was primarily a safety trial — but 10 patients showed marked improvements in vision, and the eyesight in another seven seems to have stabilized.

Previous studies showed that, in depressed patients, lipid rafts sequester a protein involved in cell signaling, called GαS, keeping it from doing its job.

The study, published Feb. 5 in Nature Neuroscience, showed that the patients» nerve cells — converted directly from patients» skin cells — exhibited «symptoms» of the disorder, including DNA damage, dysfunctional mitochondria and cell death.

«In theory, we could model progression of the disease by reprogramming skin cells from patients at a range of ages, including before symptoms begin.

In a group of patients who underwent surgery for epilepsy, over half had stem cells where healthy individuals do not have them, according to a study from Sahlgrenska Academy.

To develop their «disease in a dish» model, the team took skin cells from patients with Allan - Herndon - Dudley syndrome and reprogrammed them into induced pluripotent stem cells, which then can be developed into any type of tissue in the body.

In the March 22 online issue of Cancer Research, scientists explained how they injected triple negative breast cancer stem cells from patients into mice.

These «organoids» appear to be different when built with cells from autistic patients compared with when they are built with cells from the patients» non-autistic family members, researchers report July 16 in Cell.

In blood samples from these patients, the researchers found an increase in the percentage of gamma delta T cells, similar to what they observed in mice, which remained stable over yearIn blood samples from these patients, the researchers found an increase in the percentage of gamma delta T cells, similar to what they observed in mice, which remained stable over yearin the percentage of gamma delta T cells, similar to what they observed in mice, which remained stable over yearin mice, which remained stable over years.

Scientists could build chips containing cells from patients with specific genetic mutations, which could predict drug responses in specific populations, as well as personalized chips that predict an individual's drug response.

His lab differentiates iPSCs from autistic patients into neurons and glial cells, which they suspect may be releasing cytokines at levels higher than normal in autistic patients.

For example, a consortium of research groups called the London Project to Cure Blindness aims to test RPE transplants from embryonic stem cells in patients with macular degeneration this year.

In collaboration with Anna Pyle, Howard Hughes Medical Institute investigator and professor in the Department of Molecular, Cellular and Developmental Biology at Yale, Patrizio and his team studied samples from 20 cumulus cells in 15 patients younger than age 35 and in those age 40 and oldeIn collaboration with Anna Pyle, Howard Hughes Medical Institute investigator and professor in the Department of Molecular, Cellular and Developmental Biology at Yale, Patrizio and his team studied samples from 20 cumulus cells in 15 patients younger than age 35 and in those age 40 and oldein the Department of Molecular, Cellular and Developmental Biology at Yale, Patrizio and his team studied samples from 20 cumulus cells in 15 patients younger than age 35 and in those age 40 and oldein 15 patients younger than age 35 and in those age 40 and oldein those age 40 and older.

The decision was seen as an effort to mollify the religious fundamentalists at the core of Bush's political support who are ideologically opposed to deriving the cells from frozen embryos in fertility clinics and scientists and patients who hope that the cells could be used to help patients with Parkinson's, Alzheimer's, spinal - cord injuries, and diabetes.

If they succeed, they can be reasonably confident that epithelial cells can be taken from a patient and used to regenerate damaged tissue in that same person.

Now, doctors at the University of Kiel in Germany have neatly bypassed the initial bone removal procedure and instead grown the required bone from stem cells in the patient's own bone marrow.

Researchers from Duke University had previously used CRISPR to correct genetic mutations in cultured cells from Duchenne patients, and other labs had corrected genes in single - cell embryos in a laboratory environment.

Novartis, for example, spent $ 43 million on a manufacturing facility in Morris Plains, New Jersey, and last week it released results from a lymphoma trial in which cells were frozen and flown to and from patients in 10 countries.

Beginning in the 1970s, physicians learned how to harvest skin stem cells from a patient with extensive burn wounds, grow them in the laboratory, then apply the lab - grown tissue to close and protect a patient's wounds.

They also determined that blocking the enzyme reduces multiple myeloma regeneration in experimental models derived from patient cancer cells.

Other molecular information from patients may reveal these so - called «hidden responders,» according to a Penn Medicine study in Cell Reports this week.

So far, researchers with the Allen Institute for Brain Science in Seattle have described the intricate shapes and electrical properties of about 100 nerve cells, or neurons, taken from the brains of 36 patients as they underwent surgery for conditions such as brain tumors or epilepsy.

In preclinical studies using cell models that mimicked liver cells of patients with the rare disease Friedreich's ataxia (FA), a widely used cholesterol - lowering drug increased a precursor of HDL (high - density lipoprotein), the «good cholesterol,» according to new research published in PLOS ONE from the Perelman School of Medicine at the University of PennsylvaniIn preclinical studies using cell models that mimicked liver cells of patients with the rare disease Friedreich's ataxia (FA), a widely used cholesterol - lowering drug increased a precursor of HDL (high - density lipoprotein), the «good cholesterol,» according to new research published in PLOS ONE from the Perelman School of Medicine at the University of Pennsylvaniin PLOS ONE from the Perelman School of Medicine at the University of Pennsylvania.

«I'm working with Professor Richard Oreffo and Dr Rahul Tare from the University's Centre for Human Development, Stem Cells and Regeneration who are trying to create and grow cartilage in the lab using a patients» own (autologous) stem cells to then be implanted back into the patient if they have a cartilage defect,» she explCells and Regeneration who are trying to create and grow cartilage in the lab using a patients» own (autologous) stem cells to then be implanted back into the patient if they have a cartilage defect,» she explcells to then be implanted back into the patient if they have a cartilage defect,» she explains.

In the future the researchers see using stem cells taken from patients to grow new bones.

Based on these ex vivo experiments (in cells isolated from patients and then exposed to PD - L1 blocking agents outside of the body), they predict that when actual patients are given PD - L1 blocking agents, their viral load at the time will influence the «net» outcome, i.e., whether the blockage boosts or weakens the overall anti-HIV immune response.

In addition, they found that PD - L1 blockade increased virus production in the cell culture from such patientIn addition, they found that PD - L1 blockade increased virus production in the cell culture from such patientin the cell culture from such patients.

If the procedure works in humans, it would enable donated livers from humans, and possibly even from pigs, to be re-coated with a patient's own cells, reducing the likelihood of organ rejection.

«We concluded that stem cells used in cardiac therapy should be drawn from healthy donors or be better genetically engineered for the patient.»

However, for patients with lymphoma, it may be a rather different story, as new research from the University of Copenhagen shows that toxins in the staphylococcus bacteria help cancer cells gain control over healthy cells.

The study also suggests that targeting the machinery that makes cells mobile, rather than targeting the tissue - clearing process — which has been tested in patients but has not been very effective — may be a better treatment strategy to stop cancers from spreading.

The Boston patients, in contrast, are free of the virus thanks to a combination of a bone marrow transplant plus continuing antiretroviral drugs to stop newly donated immune cells from being infected.

Novel abnormalities in the FGFR gene, called FGFR fusions, were identified in a spectrum of cancers, and preliminary results with cancer cells harboring FGFR fusions suggested that some patients with these cancers may benefit from treatment with FGFR inhibitor drugs, according to data published in Cancer Discovery, a journal of the American Association for Cancer Research.

These were released into tumour cells that had been taken from glioblastoma patients and grown in the lab.